Dr. David S. Kung Recruits Patients for Clinical Study of HydraSolve® vs. Traditional Liposuction in Flanks
Treatment
January, 2016. Tustin, CA. – Andrew
Technologies LLC announces that Dr. David S. Kung of Kung Plastic
Surgery, P.A. is now recruiting patients for a multicenter, controlled clinical trial of HydraSolve® vs. suction assisted
liposuction (the most common form of traditional liposuction). If qualified for
the study, patients will receive extraction of excess fat in their flanks (low back) and will be compensated for their
time as they report on their progress in recovery.
The purpose of this research is to
compare the use of two different methods of liposuction, HydraSolve® and suction-assisted
liposuction. All devices used in this study are FDA cleared. This
study is being done to determine if one method of liposuction is better than
the other, or if they are the same.
HydraSolve® employs Tissue Liquefaction Technology as a safe non-cutting energy source which transitions fat tissue from a
solid to a liquid; without affecting blood vessels, nerves and connective
tissues so fat tissue can be
aspirated from the body through a tiny incision.
Suction assisted liposuction is
different from HydraSolve® because
the mechanism of action which, allows removal of fat tissue, is the cutting of
fat tissue (and non-targeted tissues) into small pieces to allow the fat to be
removed. Both methods of liposuction used in this study, HydraSolve® and suction-assisted, are FDA cleared.
Patients who agree to take part in this study, will need to be seen a total of four (4) visits with each visit lasting
approximately 30 to 45
minutes.
Study subjects may experience one or
more of the known liposuction risks indicated below from being in this study.
These risks are: infection, bleeding, seroma formation, contour irregularity,
numbness or tingling, prolonged swelling, skin necrosis, fluid imbalance,
unintended perforation of an internal organ, and embolism which in some
instances can be fatal.
Interested patients should call (301) 986-8878 to schedule a 1-hour consultation with Dr. Kung to verify eligibility.
Interested patients should call (301) 986-8878 to schedule a 1-hour consultation with Dr. Kung to verify eligibility.
About HydraSolve®
HydraSolve® is a body contouring device based on
the same patented Tissue Liquefaction Technology™ that was launched in 2003 by
Alcon as the AquaLase® Liquefaction
Device for precision cataract surgery. Hydrasolve® combines natural saline solution with low levels
of temperature and pressure, to liquefy only targeted fat tissue. Because fat
tissue is liquefied, the cutting of fat by forceful thrusts of the cannula is
no longer required. The specially designed HydraSolve® cannula is manufactured with aperture
edges that have a rounded radius of curvature that do not cut tissue. It
is the energized saline stream, inside the cannula, that liquefies targeted fat
tissue while not liquefying or cutting blood vessels, nerves or connective
tissue. HydraSolve® achieves
liquefaction of fat tissue by cell disaggregation, not by emulsification and
the lysing of cell membranes. HydraSolve® is the first liposuction device
FDA cleared for autologous fat transfer. For more information, please refer to www.hydrasolve.com HydraSolve® is designed to contour the body by
removing localized deposits of excess fat and is not intended to treat obesity.
Liposuction is a surgical procedure that has risks similar to other minimally
invasive cosmetic surgeries.
About Andrew Technologies, LLC
Andrew
Technologies, founded in 2007, is a medical technology company committed to
improving patients’ lives through body aesthetics and pursuit of surgical
applications of Tissue Liquefaction Technology. In addition to HydraSolve®,
Andrew Technologies has an impressive research pipeline to include minimally
invasive surgery to correct type 2 diabetes and adipose stem cell isolation. Andrew Technologies is a privately
funded company.
